“jounce-therapeutics” Archives

Entry Author Date Location
RaNA CEO Renaud Turns To A Former Backer To Lead $55M Series B 07/23/15 Boston
Ex-AstraZeneca Exec to Lead Surface’s “Next-Gen” Immuno-Oncology Plan 05/07/15 Boston
Adaptive Reels in Whopping $195M For Immuno-Sequencing Work 05/06/15 Seattle
With $46M Haul, MyoKardia Becomes Third Rock’s Latest IPO Prospect 04/30/15 San Francisco
East Coast Biotech Roundup: Forum, Crossovers, Immuno-Oncology & More 04/24/15 Boston
Crossovers Arm Jounce With $56M For “Next Step” Immuno-Oncology 04/23/15 Boston
Jounce Therapeutics Secures $56,000,000 Series B Funding 04/23/15 Boston
East Coast Biotech Roundup: Acceleron, Seres, Sage, & More 07/18/14 Boston
East Coast Biotech Roundup: Regeneron, Sarepta, Jounce, & More 07/11/14 Boston
New Jounce CEO Aims to Place the Right Immuno-Oncology Bets 07/11/14 Boston
Jounce Taps Merck Vet to Lead Cancer Drug Push 07/10/14 Boston
East Coast Biotech Roundup: Gerngross, Akili, Intercept, & More 01/10/14 Boston
Juno Therapeutics Grabs $120M to Coax Immune System to Fight Cancer 12/03/13 Seattle
Armo BioSciences Joins the Cancer Immunotherapy Party With $20M 11/25/13 San Francisco
The Biotech Startup Class of 2013: Don’t Worry, It’s a Short List 11/18/13 National
Q&A With Bob Tepper on What’s Next for Third Rock Ventures 03/26/13 Boston
East Coast Life Sciences Roundup: Jounce, Tokai, Lux, & More 02/15/13 National
Third Rock’s Latest, Jounce, Grabs $47M For Cancer Immunotherapy 02/14/13 Boston
Jounce Therapeutics Garners $47,000,000 Series A Financing Round 02/14/13 Boston
Page 1 of 1